Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

Publisher： Karger

E-ISSN： 1421-9875|31|3-4|328-335

ISSN： 0257-2753

Source： Digestive Diseases, Vol.31, Iss.3-4, 2013-11, pp. : 328-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

By  

Digestive Diseases, Vol. 33, Iss. 1, 2015-09 ,pp. : 95-104

Karger

Access to resources Recommend Favorite

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 91-100

Karger

Access to resources Recommend Favorite

Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases

By Tursi Antonio   Elisei Walter   Giorgetti GianMarco   Picchio Marcello   Brandimarte Giovanni  

Scandinavian Journal of Gastroenterology, Vol. 48, Iss. 11, 2013-11 ,pp. : 1359-1360

Informa Healthcare

Access to resources Recommend Favorite

Chemokines in Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 28, Iss. 3, 2010-09 ,pp. : 386-394

Karger

Access to resources Recommend Favorite

Antibiotics and Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 31, Iss. 3-4, 2013-11 ,pp. : 379-384

Karger

Access to resources Recommend Favorite